TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04449939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody
Study: NCT03239782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
Study: NCT03411252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Myrbetriq (Mirabegron) tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron 50 MG
Description: Myrbetriq (Mirabegron) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill manufactured to mimic Mirabegron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Mirabegron
Study: NCT02627287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlexPen®
Description: For subcutaneously (s.c. under the skin) injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3316 pen-injector
Description: For subcutaneously (s.c. under the skin) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: For subcutaneously (s.c. under the skin) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: For subcutaneously (s.c. under the skin) injection
Study: NCT02897531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ES anastomosis
Description: The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SS anastomosis
Description: The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
Study: NCT01773343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Fractionel CO2 laser: 1 versus 3 months intervals

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Fractionel CO2 laser: 1 versus 3 months intervals
Study: NCT06351319

Intervention type: DIAGNOSTIC_TEST
Intervention: SVM model
Description: Bronchoscopic ultrasound images were analyzed according to SVM mode

Intervention type: DIAGNOSTIC_TEST
Intervention: SVM model
Description: Bronchoscopic ultrasound images were analyzed according to SVM mode
Study: NCT01296464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbidopa
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Capsules
Study: NCT01981096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fibromyalgia integrative training
Description: Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
Study: NCT01738698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 40mg
Description: Oral administration of 40 mg once-daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 100mg
Description: Oral administration of 100 mg once-daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 160mg
Description: Oral administration of 160 mg once-daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once-daily for 12 weeks
Study: NCT03863405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional DMARDs
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Study: NCT01981096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Therapy focused on training in behavioral pain coping skills
Study: NCT00601653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)
Description: CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)
Description: CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
Study: NCT00004842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Oral budesonide, 9 mg daily was administered for 1 year
Study: NCT02455596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
Study: NCT03863405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional DMARDs
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablet
Study: NCT03283098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied to match active intervention.
Study: NCT00711113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: OsseoSpeed™, all dimensions
Study: NCT00607113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 15 mg/kg By Vein Over 90 Minutes Every 21 Days
Study: NCT02404844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: daily oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: daily oral
Study: NCT00454194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed disodium
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally
Study: NCT01989052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Study: NCT02808832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: 5-minute video and information sheet with a list of suggested questions to ask the provider
Study: NCT04497415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Based intervention
Description: Three minutes video of a nurse that shares her personal story
Study: NCT04927078

Intervention type: OTHER
Intervention: Observation of breathing pattern
Description: Observations will be collected using a remote vision based patient monitoring and management system.

Intervention type: OTHER
Intervention: Observation of breathing pattern
Description: Observations will be collected using a remote vision based patient monitoring and management system.
Study: NCT00620854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Salmon Calcitonin (rsCT)
Description: Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tablet
Description: 0.15 mgs recombinant salmon calcitonin, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tablet
Description: 0.2mgs recombinant salmon calcitonin, single oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray
Description: 200 IU recombinant salmon calcitonin, single intranasal spray
Study: NCT01313884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50 mg/m2/day x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg/m2 to a maximum of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2/day x 5 days followed by 2 weeks treatment-free

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Starting dose 75 mg/m2 to a maximum of 450mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 1200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
Study: NCT00607113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 15 mg/kg By Vein Over 90 Minutes Every 21 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg By Mouth Daily For 21 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg By Mouth Daily For 21 Days
Study: NCT03259048

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound
Description: Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
Study: NCT02074228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Concerta)
Study: NCT00263757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Description: Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Subjects randomized to this arm received medical management as prescribed by their cardiologist.
Study: NCT01020266

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non electroacupuncture stimulation
Description: The same procedure as electroacupuncture except stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture pretreatment
Description: According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
Study: NCT02142309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Start with 15 mg/day and advance to 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
Study: NCT04569188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: COVID-19 elderly patients treated with convalescent plasma
Study: NCT01806207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane injection
Study: NCT03311503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD34+ cell transduced with G2SCID vector
Description: single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
Study: NCT01803178

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant Sterols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Product
Study: NCT01806207

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Study: NCT02530892

Intervention type: PROCEDURE
Intervention: EmbryoHug
Description: An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo.
Study: NCT02142595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
Study: NCT03294096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routine care + Nutritional product
Description: Routine post-op care + Nutritional supplement by specific product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine post-op care
Study: NCT02142595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
Study: NCT02166632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracapsular Injection
Description: The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection
Description: The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
Study: NCT02382172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training for Autism (SCIT-A)
Description: The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
Study: NCT02085941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation using 17G Galil cryoprobe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation using 17G Galil cryoprobe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy using 18G Temno core biopsy needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy using 18G Temno core biopsy needle
Study: NCT01061307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified extruded rice
Description: fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
Study: NCT01934322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent.
Study: NCT03177707

Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness-based Therapy Group for Couples
Description: Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Therapy Group for Couples
Description: Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital.
Study: NCT03654651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate snack
Description: Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
Study: NCT02409628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EktoTherix
Description: The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
Study: NCT01795716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesylate imatinib capsule
Description: Single and multiple oral mesylate imatinib capsule 400mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec
Description: Single and multiple oral Glivec 400mg qd
Study: NCT03299621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLE (Phase Lag Entropy)
Description: Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscle Relaxant
Description: Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
Study: NCT01205646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronate therapy
Description: Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: 2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
Study: NCT03075865

Intervention type: DEVICE
Intervention: OmniMax MMF system
Description: OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
Study: NCT04036006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Based Program
Description: The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Program
Description: The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
Study: NCT02278159

Intervention type: PROCEDURE
Intervention: Peritoneal dialysis

Intervention type: PROCEDURE
Intervention: Peritoneal dialysis

Intervention type: PROCEDURE
Intervention: Peritoneal dialysis

Intervention type: PROCEDURE
Intervention: Home hemodialysis